DAIC Articles

May 31, 2022 | DAIC Articles
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease

COMPASS open label extension study results support the long-term use of XARELTO plus aspirin for vascular protection in patients with chronic CAD and/or PAD

Feb 25, 2022 | DAIC Articles
New Artificial Intelligence Tool Detects Often Overlooked Heart Diseases

Physician-scientists in the Smidt Heart Institute at Cedars-Sinai have created an artificial intelligence (AI) tool that can effectively identify and distinguish between two life-threatening heart conditions that are often easy to miss: hypertrophic cardiomyopathy and cardiac amyloidosis. The new findings were published in JAMA Cardiology.

Jan 4, 2022 | DAIC Articles
FDA Clears Novartis Inclisiran to Lower Cholesterol With Only Two Doses a Year

The U.S. Food and Drug Administration (FDA) has cleared Novartis’ inclisiran (Leqvio), the first  small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C) with two doses a year, after an initial dose and one at three months.

Aug 9, 2021 | DAIC Articles
Study Compares Interventional Pulmonary Embolism Therapy in Combination With Anticoagulation to Anticoagulation Alone

Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of the Johannes Gutenberg University of Mainz comparing use of the EkoSonic Endovascular System in combination with anticoagulation to anticoagulation alone for the treatment of acute, intermediate-high-risk […]

Filter by Journal